MTOR and non-small cell lung carcinoma: Respectively, the combined treatment inhibited the progression of non-small-cell lung cancer (NSLC) by blocking the PI3K/Akt/mTOR pathway, thus inducing cell apoptosis and limiting cell proliferation, migration, and metastasis [103].